Phase-3 trial results show COVAXIN is 77.8% effective against symptomatic COVID-19
Efficacy analysis demonstrates COVAXIN to be 93.4% effective against severe symptomatic COVID-19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant